A short history of anti-rheumatic therapy - VII. Biological agents

  • G. Pasero Università di Pisa, Italy.
  • P. Marson | piero.marson@sanita.padova.it Unità di Aferesi Terapeutica, U.O.C. Immunotrasfusionale, Azienda Ospedale Università di Padova, Italy.
  • B. Gatto Dipartimento di Scienze Farmaceutiche, Università di Padova, Italy.

Abstract

The introduction of biological agents has been a major turning-point in the treatment of rheumatic diseases, particularly in rheumatoid arthritis. This review describes the principle milestones that have led, through the knowledge of the structure and functions of nucleic acids, to the development of production techniques of the three major families of biological agents: proteins, monoclonal antibodies and fusion proteins. A brief history has also been traced of the cytokines most involved in the pathogenesis of inflammatory rheumatic diseases (IL-1 and TNF) and the steps which have led to the use of the main biological drugs in rheumatology: anakinra, infliximab, adalimumab, etanercept and rituximab.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2011-11-09
Info
Issue
Section
Survey/Comments
Keywords:
History of rheumatology, biological agents, monoclonal antibodies, cytokines
Statistics
  • Abstract views: 942

  • PDF: 896
How to Cite
Pasero, G., Marson, P., & Gatto, B. (2011). A short history of anti-rheumatic therapy - VII. Biological agents. Reumatismo, 63(3), 185-194. https://doi.org/10.4081/reumatismo.2011.185